Evidence map›Paper›PMID 42779881›Full record

ArticlebioRxiv : the preprint server for biology2026

Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants.

Caroline Kikawa, Andrew Butler, John Huddleston, Sam A Turner, Heidi Peck, Janet A Englund, Kirsten Lacombe, Michael Busch, Marion C Lanteri, Mars Stone and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Caroline KikawaDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.ORCID 0000-0002-8654-5663
Andrew ButlerDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.ORCID 0000-0003-3608-0463
John HuddlestonVaccine and Infectious Disease Division, Fred Hutch Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.ORCID 0000-0002-4250-2063
Sam A TurnerCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, The Old Schools, Trinity Ln, Cambridge CB2 1TN, United Kingdom.
Heidi PeckWHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street Melbourne, 3000, Australia.
Janet A EnglundSeattle Children's Research Institute and Department of Pediatrics, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA.ORCID 0000-0003-1134-4178
Kirsten LacombeSeattle Children's Research Institute and Department of Pediatrics, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA.
Michael BuschVitalant Research Institute, 360 Spear St Ste 200, San Francisco, CA 94105, USA.ORCID 0000-0002-1446-125X
Marion C LanteriDepartment of Laboratory Medicine, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.
Mars StoneVitalant Research Institute, 360 Spear St Ste 200, San Francisco, CA 94105, USA.
Bryan SpencerAmerican Red Cross, 180 Rustcraft Rd, Dedham, MA 02026, USA.
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington Medical Center, 1959 NE Pacific St, Seattle, WA 98195, USA.ORCID 0000-0002-7443-0527
Derek J SmithCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, The Old Schools, Trinity Ln, Cambridge CB2 1TN, United Kingdom.
Stephanie WallaceUniversity of the Sunshine Coast Clinical Trials, Sunshine Coast, Queensland, Australia.
Helen S MarshallAdelaide University, South Australia, 5005, Australia.
Shidan TosifMurdoch Children's Research Institute, University of Melbourne, The Royal Children's Hospital Melbourne, 50 Flemington Road, Parkville, Victoria, 3052, Australia.ORCID 0000-0003-0022-1009
Scott E HensleyDepts of Microbiology and Medicine, Perelman School of Medicine, University of Pennsylvania, 3451 Walnut Street, Philadelphia, PA 19104, USA.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street Melbourne, 3000, Australia.ORCID 0000-0002-7351-418X
Jesse D BloomDivision of Basic Sciences and Computational Biology Program, Fred Hutch Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.ORCID 0000-0003-1267-3408

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
Forecasting influenza evolution on a heterogeneous immune landscapeR01AI165821 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jesse D Bloom, JOHN HUDDLESTON · 2022 to 2026
$3.0M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
Next-generation sequencing-based neutralization assays to forecast influenza virus clade growth.F30AI186284 · NIAID · UNIVERSITY OF WASHINGTON · PI Caroline Sakura Kikawa · 2025 to 2026
$92k
NCI NIH HHS P30 CA015704NIAID NIH HHS F30 AI186284NIAID NIH HHS R01 AI165821NIH HHS 75N93021C00015NIH HHS S10 OD020069NIH HHS S10 OD028685
6 · The paper itself

Abstract

Human seasonal influenza evolves rapidly, necessitating twice yearly decisions about whether to update the strains in the vaccine. To help inform this decision, we have been using high-throughput sequencing-based neutralization assays to make twice yearly measurements of how recent human sera neutralize current human H3N2 and H1N1 strains. Here we provide the third installment in this series of measurements by reporting 52,268 titers representing neutralization of 148 viral strains by 355 human sera collected between April and August of 2026. Our measurements show that new H3N2 subclade K strains with mutations in antigenic region D and new H1N1 subclade D.3.1.1 strains with mutations in antigenic region Sa (such as G155E) have reduced neutralization by human sera, with notable heterogeneity in the impact of some of these mutations across sera from different individuals. This paper is accompanied by an interactive summary (https://jbloomlab.github.io/flu-seqneut-2026/summary.html) that enables detailed exploration of the results, and all titer data are publicly available for further analysis to aid vaccine antigen selection and studies of viral evolution.

Identifiers

PMID42779881
PMCPMC13596333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.